IMRALDI — Total Revenue
Biogen IMRALDI — Total Revenue increased by 14.0% to $49.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 4.6%, from $47.40M to $49.60M. Over 4 years (FY 2021 to FY 2025), IMRALDI — Total Revenue shows a downward trend with a -5.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates growing market share or successful commercial execution for the biosimilar, while a decrease suggests heightened competition or pricing pressure in the biosimilar market.
Detailed definition
This metric represents the total gross revenue generated from the sale of the biosimilar product Imraldi. It reflects th...
Peer comparison
Comparable to biosimilar revenue streams reported by pharmaceutical peers, often benchmarked against the original reference product's market share and overall biosimilar market penetration rates.
biib_segment_imraldi_total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $55.60M | $57.40M | $62.50M | $57.10M | $57.60M | $57.70M | $52.10M | $54.40M | $58.80M | $54.40M | $54.50M | $54.80M | $53.20M | $54.10M | $51.00M | $47.40M | $46.70M | $52.60M | $43.50M | $49.60M |
| QoQ Change | — | +3.2% | +8.9% | -8.6% | +0.9% | +0.2% | -9.7% | +4.4% | +8.1% | -7.5% | +0.2% | +0.6% | -2.9% | +1.7% | -5.7% | -7.1% | -1.5% | +12.6% | -17.3% | +14.0% |
| YoY Change | — | — | — | — | +3.6% | +0.5% | -16.6% | -4.7% | +2.1% | -5.7% | +4.6% | +0.7% | -9.5% | -0.6% | -6.4% | -13.5% | -12.2% | -2.8% | -14.7% | +4.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's imraldi — total revenue?
- Biogen (BIIB) reported imraldi — total revenue of $49.60M in Q1 2026.
- How has Biogen's imraldi — total revenue changed year-over-year?
- Biogen's imraldi — total revenue increased by 4.6% year-over-year, from $47.40M to $49.60M.
- What is the long-term trend for Biogen's imraldi — total revenue?
- Over 4 years (2021 to 2025), Biogen's imraldi — total revenue has grown at a -5.0% compound annual growth rate (CAGR), from $233.40M to $190.20M.
- What does imraldi — total revenue mean?
- The total sales revenue generated by the Imraldi biosimilar product.